株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界のアルツハイマー病診断および治療薬市場:治療薬、診断法、地域別 - 成長、動向、予測

Alzheimer's Disease Diagnostics and Therapeutics Market - Growth, Trends, and Forecast (2019 - 2024)

発行 Mordor Intelligence LLP 商品コード 661016
出版日 ページ情報 英文 114 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=110.75円で換算しております。
Back to Top
世界のアルツハイマー病診断および治療薬市場:治療薬、診断法、地域別 - 成長、動向、予測 Alzheimer's Disease Diagnostics and Therapeutics Market - Growth, Trends, and Forecast (2019 - 2024)
出版日: 2019年02月01日 ページ情報: 英文 114 Pages
概要

世界のアルツハイマー病診断および治療薬市場は、2017年に71億米ドルと評価され、2018年から2023年にかけては6.7%のCAGRで推移することが予測されています。地域別では、北米市場が最大のシェアを握っています。

当レポートでは、世界のアルツハイマー病診断および治療薬市場を調査し、市場の概要、治療薬・診断法・地域別の市場規模の推移と予測、市場動向、市場シェア、成長要因・阻害要因ならびに市場機会・課題の分析、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 イントロダクション

  • 市場の定義

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 主な影響要因

第5章 市場の概要

  • 現在の市場シナリオ
  • ファイブフォース分析
    • 買い手の交渉力
    • 供給企業の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係

第6章 成長要因、阻害要因、市場機会、課題の分析

  • 成長要因
    • 医薬品開発のためのバイオマーカーへの投資
    • パイプライン医薬品の開発拡大
    • アルツハイマー病の罹患率および有病率の上昇
    • 早期発見に向けた先進診断の増加と精密医薬品の開発
    • 新興診断技術の台頭
  • 市場の阻害要因
    • 症状の早期診断における課題
    • 後期臨床試験の失敗による市場の衰退
    • 創薬と医薬品開発のための代替マーカーの欠如
    • 不十分な研究資金と不確実で長期的なプロセス
  • 市場機会
  • 主な課題

第7章 市場セグメンテーション

  • 治療薬別
    • コリンエステラーゼ阻害薬
    • NMDA受容体拮抗薬
    • その他
  • 診断法別
    • 脳イメージング
    • 脳脊髄液(CSF)検査
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • 中東・アフリカ
    • 南米

第8章 競合情勢

  • 合併および買収分析
  • 合意、コラボレーション、パートナーシップ
  • 新製品の発売

第9章 主要企業

  • F. Hoffmann-La Roche
  • Novartis
  • Merck & Co.
  • Pfizer Inc
  • エーザイ
  • Biogen Inc
  • Johnson & Johnson
  • Eli Lily & Co
  • Amarantus Bioscience Holdings
  • DiaGenic ASA
  • Navidea Biopharmaceuticals Holdings Inc.
  • GE Healthcare

第10章 市場の将来展望

目次
Product Code: 53669

Market Overview

The global Alzheimer's disease diagnostics and therapeutics market was valued at USD 7,537.4 million in 2018, and is estimated to be valued at USD 11,138.2 million in 2024, witnessing a CAGR of 6.7%. The key factors propelling the growth of this market are investment in biomarkers for drug development, increasing pipeline drug development, increasing sophisticated diagnostics for early detection, along with more precise drug development, and emerging novel diagnostics technologies.

Alzheimer's disease is one of the most prevalent types of dementia that occurs worldwide. According to the Alzheimer's disease facts and figures, it is estimated that in every 33 seconds, a new case of Alzheimer's disease occurs, leading to high prevalence of the disease, of almost 35 million patients, around the world. The development of clinical diagnostics and therapeutics for Alzheimer's disease (AD) and other neurodegenerative conditions is becoming very important. In about 10-15% cases, the clinical diagnosis of AD is inaccurate. So, certain biomarkers that may improve the accuracy of the diagnosis are used. Biomarkers are neurochemical indicators used to determine the risk or prevalence of the disease.

Investing in biomarkers for drug development and early detection of AD acts as a major driver, and fuels the growth of the Alzheimer's disease diagnostics and therapeutics market, globally.

Scope of the Report

As per the scope of the report, Alzheimer's disease (AD) is a progressive, degenerative disorder that attacks the brain's nerve cells or neurons, resulting in loss of memory, thinking and language skills, and behavioural changes.

Key Market Trends

Cholinesterase Inhibitors are Expected to hold the Highest Market Share in the Therapeutics Segment

In the therapeutics segment of the Alzheimer's disease diagnostics and therapeutics market. Cholinesterase inhibitors are believed to have the largest market size and are expected to witness a CAGR of 6.4% during the forecast period.

Cholinesterase inhibitors are used for the treatment of Alzheimer's. These cholinesterase inhibitors are approved by the US FDA. Most physicians and perhaps most patients consider cholinergic drugs. Donepezil, galantamine, and rivastigmine are the generic names of cholinesterase inhibitors, which are likely to be the first-line pharmacotherapy choice for mild to moderate Alzheimer's disease. These drugs have somewhat different pharmacological properties, but all of them work by the same mechanism, which involves inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme acetylcholinesterase.

The market is dominated by leading brands, such as Aricept, Exelon, and Reminyl; Aricept, whose active ingredient is a cholinesterase inhibitor, holds the largest market share. Several clinical trials are ongoing on cholinesterase inhibitors to increase drug efficacy and decrease adverse effects. Hence, oeing to the developments, the cholinesterase inhibitor drugs market is expected to grow during the forecast period.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America currently dominates the market for Alzheimer's disease diagnostics and therapeutics ,and is expected to continue its stronghold for a few more years. The United States holds the largest share of the global Alzheimer's disease diagnostics and therapeutics market. According to the Alzheimer's Association, more than 5 million Americans suffer from Alzheimer's, as of 2017. The United States is considered to be the global leader in Alzheimer's disease intervention and management. America has a large pool of biopharmaceutical companies, which cumulatively have 85 drugs for combating Alzheimer's disease in various stages of the pipeline. Hence, the market is expected to register a healthy CAGR over the forecast period.

Competitive Landscape

The Alzheimer's disease diagnostics and therapeutics market is moderately competitive and consists of several major players. With technological advancements and product innovation, mid-size to smaller companies are increasing their market presence, by introducing new technologies with better results. Companies, like F. Hoffmann-La Roche, Novartis AG, Merck & Co., Pfizer Inc., and Eli Lily & Co., hold a substantial market share in the Alzheimer's disease diagnostics and therapeutics market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Investment in Biomarkers for Drug Development
    • 4.2.2 Increasing Pipeline Drug Development
    • 4.2.3 Increasing Sophisticated Diagnostics for Early Detection and More Precise Drug Development
    • 4.2.4 Emerging Novel Diagnostic Technologies
  • 4.3 Market Restraints
    • 4.3.1 Early Diagnosis of the Indication is Challenging
    • 4.3.2 Decline in the Market Due to Failures of Late-stage Drugs
    • 4.3.3 Lack of Surrogate Markers for Drug Discovery and Drug Development
    • 4.3.4 Insufficient Research Funding and Lengthy, Expensive, and Uncertain Process
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Therapeutics
    • 5.1.1 Cholinesterase Inhibitors
    • 5.1.2 NMDA Receptor Antagonists
    • 5.1.3 Other Therapeutics
  • 5.2 By Diagnostics
    • 5.2.1 Brain Imaging
    • 5.2.2 CFS Test for Alzheimer's Disease
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East & Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East & Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 F. Hoffmann-La Roche
    • 6.1.2 Novartis AG
    • 6.1.3 Merck & Co. Inc
    • 6.1.4 Pfizer Inc
    • 6.1.5 Eisai Co. Ltd
    • 6.1.6 Biogen Inc
    • 6.1.7 Johnson & Johnson
    • 6.1.8 Eli Lilly & Company
    • 6.1.9 Amarantus Bioscience Holdings Inc
    • 6.1.10 Diagenic ASA
    • 6.1.11 Navidea Biopharmaceuticals
    • 6.1.12 GE Healthcare

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top